U.S. Subsidiary Of India’s Sun To Double Plant Size, Add Staff
This article was originally published in PharmAsia News
Executive Summary
Sun Pharmaceuticals of India plans to double the size of the facilities of its U.S.-based subsidiary, Caraco Pharmaceuticals. Caraco, an independent arm of Sun, is based in Detroit where it plans a $22 million expansion and increase its staff over the next five years. Sun's U.S. arm markets 17 pharmaceuticals in the country, with another 27 in the pipeline for U.S. FDA approval. In addition, Caraco markets Sun's Indian products in the United States. (Click here for more